A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

Condition:   Esophageal Squamous Cell Carcinoma
Interventions:   Drug: SHR-1210;   Drug: Placebo
Sponsors:   The First Affiliated Hospital of Zhengzhou University;   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting

http://bit.ly/2sYUCC3